RecruitingNot Applicable

Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency

Switzerland28 participantsStarted 2026-01-09

Plain-language summary

The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult healthy controls
✓. No medication (including hormonal contraception)
✓. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months
✓. Confirmed diagnosis of AVP-Deficiency
✓. Age ≥ 18 years
✓. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months or in the case of hormone replacement therapy, with a 1-week pause from the respective treatment

Exclusion criteria

✕. Participation in a trial with investigational drugs within 30 days
✕. BMI \>30
✕. Age \>50
✕. Illicit substance use (except for cannabis) during the last 30 days
✕. Consumption of alcoholic beverages \>15 drinks/week
✕. Tobacco smoking \>10 cigarettes/day
✕. Pregnancy and breastfeeding
✕. Hormonal contraception

What they're measuring

Relative Change in Plasma Oxytocin

Timeframe: From baseline (0 min) to 300 minutes post-dose.

Relative Change in Neurophysin-1

Timeframe: From baseline (0 min) to 300 minutes post-dose.

Trial details

NCT IDNCT07361263

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02

Contact for this trial

Andi Nikaj, MD

+41 61 328 57 43 andi.nikaj@usb.ch

View on ClinicalTrials.gov More AVP Deficiency trials